请输入您要查询的百科知识：

　

词条 Arie Belldegrun
释义

  1. Early life and academia

  2. Career ventures

     Agensys  Cougar Biotechnology  Two River  Kite Pharma  Vida Ventures  Allogene Therapeutics  Other board memberships 

  3. Personal life

  4. References

  5. External links

{{resume like|date=August 2018}}{{Infobox person
|name = Arie S. Belldegrun
|image =
|image_size =
|alt =
|caption =
|birth_name =
|birth_date = {{birth year and age|1949}}
|birth_place = Israel
|residence = Los Angeles, California
|citizenship = Israeli and American
|education =
|alma_mater = Hadassah Medical Center
Weizmann Institute of Science
|occupation =
|years_active = 1988–present
|net_worth = {{increase}} US$1 billion (2016)[1]
|boards =
|spouse = Rebecka Belldegrun
|children = 4
|parents =
|relatives = Poju Zabludowicz (brother-in-law)
Anita Zabludowicz (sister-in-law)
|known_for = Chairman, president and CEO of Kite Pharma
|signature =
|signature_alt=
|website =
}}

Arie S. Belldegrun (born 1949), FACS, is an Israeli-born American urologic oncologist, businessman and investor.

Early life and academia

Belldegrun was born in Israel. He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979.[2] He completed his urologic surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988.[2] He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.[3][4] Belldegrun is the director of the UCLA Institute of Urologic Oncology, professor of urology, and chief of the Division of Urologic Oncology at the David Geffen School of Medicine.[5][6][7]

Career ventures

Agensys

In 1996, Belldegrun established Agensys, an early-stage privately held biotechnology company based in Los Angeles, that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. He served as its founding chairman of the board of directors from 1996 to 2002, and then as a director until December 2007, when Agensys was acquired by Astellas Pharma in a deal valued at $537 million.[8][9]

Cougar Biotechnology

Belldegrun has been the founding vice chairman of the board of directors and chairman of the scientific advisory board of Cougar Biotechnology since 2003, a Los Angeles-based company with a focus in the field of oncology. In July 2009, the company was acquired by Johnson & Johnson in a $970 million transaction. In April 2011, the United States Food and Drug Administration approved abiraterone acetate (Zytiga), Cougar’s lead product, for late-stage prostate cancer.[10][11]

Two River

Since 2008, Belldegrun has been the chairman and partner of Two River, a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.[12]

Kite Pharma

Belldegrun was the founder, chairman, president and CEO of Kite Pharma which he founded in 2009. Kite Pharma is a Santa Monica-based, clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT) designed to restore the immune system's ability to recognize and eradicate tumors.[13] The company went public in June 2014. On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal,[14] equating to $180 cash per share. The deal will add the promising CAR-T candidate to Gilead's existing portfolio.[15] The acquisition was completed in October 2017.[16] In October 2017, Kite Pharma’s therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.[17]

Vida Ventures

Belldegrun is the co-founder and senior managing director of Vida Ventures, a Boston-based life sciences investment firm founded in 2017 by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Its mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida Ventures has a bicoastal presence and as of April 2018 has approximately $295 million in assets under management. Companies in its portfolio include Allogene Therapeutics, Kronos Bio, A2 Biotherapeutics, Homology Medicines, Praxis Precision Medicines, Pionyr Immunotherapeutics and Sutro Biopharma.[18][19][20][21][22]

Allogene Therapeutics

Belldegrun is the co-founder and executive chairman of Allogene Therapeutics ({{NASDAQ|ALLO}}), a San Francisco-based biotechnology company founded in 2017. Allogene has raised $300 in Series A fundraising, and $120 million in a private financing round.[23][24][25][26] On October 11, 2018, Allogene Therapeutics raised $324 million in an initial public offering on the NASDAQ, listing under the ticker "ALLO".[27][28]

Other board memberships

Belldegrun also serves as a member of the following boards:[29]

  • Kronos Bio - chairman (since May 2018)[30]
  • Fosun Kite – vice chairman of the board of directors (since January 2017)[31]
  • UroGen Pharma (NASDAQ: URGN) – chairman (since October 2012)
  • Oncura – chairman of the medical advisory board
  • Roei Medical Technologies – chairman of the medical advisory board
  • Pontifax – director
  • LSM at the University of Pennsylvania – member of the advisory board[32]
  • Parker Institute for Cancer Immunotherapy – member of the strategic advisory group[33]

In the past, Belldegrun served as a member of a number of boards, including:[29]

  • Cell Design Labs – director (June 2016 to December 2017)
  • Arno Therapeutics (OTCBB: ARNI) – chairman (March 2008 to December 2017)
  • Teva ({{NYSE|TEVA}}) – director and vice chairman of the science & technology committee (February 2013 to January 2017)[34]
  • SonaCare Medical (formerly Ushifu) – director and urological advisor (September 2009 to 2014)
  • Capricor Therapeutics (formerly Nile Therapeutics) – director (September 2009 to November 2013)
  • Talon Therapeutics (formerly Hana Biosciences) – director, chairman of the compensation committee and member of the nominating & governance committee (April 2004 to December 2009)
  • Paramount Acquisition – director (June 2005 to January 2008)
  • Chem Rx Corporation – director (June 2005 to January 2008)
  • RENCAREX at Wilex AG – chairman of the medical advisory board
  • Email Real Estate.com – director

Personal life

In 2014, according to the Bloomberg Pay Index, Belldegrun was ranked the 8th highest-paid executive in the United States, with a pay package valued at $95.2 million.[35]

In 2015, The Hollywood Reporter's annual Hollywood's Top Doctors list included Belldegrun as one of the highest-rated urologists.[36]

Belldegrun was featured in the 2017 edition of the LA500-LA's Most Influential People, compiled by the Los Angeles Business Journal,[37] and has been named Business Leader of the Year for 2018 in the Health Care category for a life dedicated to finding cures for cancer.[38] He was also featured in the CEO Today USA Awards 2017 which celebrate the success, innovation and strategic vision of CEOs across a number of sectors, industries within the US, identifying the most successful, innovative and forward-thinking CEOs in business today.[39] In June 2018, Belldegrun received the EY Master Entrepreneur Award at the Entrepreneur of the Year 2018 Awards.[40]

Belldegrun has written over 500 scientific publications related to urologic oncology, and has authored several books on prostate and kidney cancers.[41][42] He was one of the speakers at the Milken Institute Global Conference 2013,[43] delivered the keynote Andrew C. Novick Memorial Lecture at the Ninth International Kidney Cancer Symposium,[44] and regularly presents at the Annual J.P. Morgan Healthcare Conference.[45] It was announced that Belldegrun will present at the 34th Annual J.P. Morgan Healthcare Conference in January 2016.[46]

References

1. ^"100 העשירים בישראל 2016" (in Hebrew). Forbes Israel. 7 September 2016. Retrieved 7 September 2016.
2. ^1 "Curriculum Vitae", InfoFAQ, July 2007. Retrieved on 22 June 2013.
3. ^[https://www.reuters.com/article/2008/04/29/idUS155097+29-Apr-2008+PRN20080429 "Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner"]. Reuters. 29 April 2008. Retrieved 25 June 2013.
4. ^"Arie Belldegrun, MD" {{webarchive |url=https://web.archive.org/web/20130715082356/http://www.uclahealth.org/body.cfm?xyzpdqabc=0&id=479&action=detail&ref=11679 |date=July 15, 2013 }}, UCLA Health. Retrieved on 25 June 2013.
5. ^"Arie Belldegrun, M.D.", David Geffen School of Medicine. Retrieved on 25 June 2013.
6. ^"Arie Belldegrun, M.D.", USRF. Retrieved on 23 June 2013.
7. ^"Advisory Board", Penn LSM. Retrieved on 28 August 2013.
8. ^Moster, Roxanne & Champeau, Rachel (27 November 2007). "UCLA scientists' biotech firm to be acquired by pharmaceutical corp.". UCLA Newsroom. Retrieved 25 June 2013.
9. ^"Board of Directors" {{webarchive |url=https://web.archive.org/web/20130630123628/http://www.nilethera.com/about_bod.html |date=June 30, 2013 }}, Nile Therapeutics. Retrieved on 25 June 2013.
10. ^"Johnson & Johnson Completes Acquisition of Cougar Biotechnology" {{webarchive |url=https://web.archive.org/web/20121101100520/http://www.cougarbiotechnology.com/pr071009.html |date=November 1, 2012 }}. Cougar Biotechnology. 10 July 2009. Retrieved 25 June 2013.
11. ^"Board of Directors", Arno Therapeutics. Retrieved on 25 June 2013.
12. ^"Company Overview of Two River Group Holdings, LLC", Businessweek. Retrieved on 26 June 2013.
13. ^"About Kite Pharma" {{webarchive |url=https://web.archive.org/web/20150121074348/http://www.kitepharma.com/c/company/index.php |date=January 21, 2015 }}. Kite Pharma. Retrieved 21 January 2015.
14. ^http://uk.reuters.com/article/us-kite-pharma-m-a-gilead-sciences-idUKKCN1B810Y
15. ^{{cite web|url=http://www.fiercepharma.com/pharma/gilead-grabs-kite-for-11-9b-thrusting-itself-to-front-car-t-field |title=Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy |website=fiercepharma.com |date=2017-08-28 |accessdate=2017-08-29}}
16. ^{{Cite web|url=http://www.gilead.com/news/press-releases/2017/10/gilead-sciences-completes-acquisition-of-kite-pharma-inc|title=Gilead {{!}} Investors {{!}} News Release|website=investors.gilead.com|access-date=2017-10-29}}
17. ^"Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy". Gilead. 18 October 2017. Retrieved 24 December 2017.
18. ^Stendahl, Max (15 December 2017). [https://www.bizjournals.com/boston/news/2017/12/15/vida-ventures-boston-s-newest-healthcare-vc-firm.html "Vida Ventures, Boston’s newest healthcare VC firm, unveils $255M fund"]. Boston Business Journal. Retrieved 24 December 2017.
19. ^Densford, Fink (18 December 2017). "Boston VC firm Vida Ventures unveils $255m healthcare fund". Mass Device. Retrieved 24 December 2017.
20. ^[https://vidaventures.com/about/ "About Us - Vida Ventures"]. Vida Ventures. Retrieved on 15 June 2018.
21. ^[https://www.businesswire.com/news/home/20180403005767/en/Vida-Ventures-Unveils-Next-Generation-Life-Sciences-Venture "Vida Ventures Unveils Next-Generation Life Sciences Venture Firm with $295 Million Under Management and an Investment in Allogene Therapeutics"]. BusinessWire. 3 April 2018. Retrieved 3 April 2018.
22. ^Dearment, Alaric (26 July 2018). [https://medcitynews.com/2018/07/sutro-raises-85-4-million-in-series-e-round-to-advance-blood-cancer-solid-tumor-drugs/ "Sutro raises $85.4 million in Series E round to advance blood cancer, solid tumor drugs"]. MedCityNews. Retrieved 31 July 2018.
23. ^"Allogene Therapeutics". Allogene Therapeutics. Retrieved on 3 April 2018.
24. ^Herper, Matthew (3 April 2018). [https://www.forbes.com/sites/matthewherper/2018/04/03/raising-300-million-kite-execs-partner-with-pfizer-to-disrupt-their-last-cancer-treatment/#21c971f432a2 "They're Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again"]. Forbes. Retrieved on 3 April 2018.
25. ^Carroll, John (3 April 2018). [https://endpts.com/arie-belldegrun-raises-300m-grabs-pfizers-allogeneic-car-t-portfolio-and-launches-a-groundbreaking-drive-to-commercialization/ "Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization"]. Endpoint News. Retrieved on 3 April 2018.
26. ^Taylor, Phil (6 September 2018). [https://www.fiercebiotech.com/biotech/allogene-raises-120m-more-for-off-shelf-car-t-programs "Allogene raises another $120M for off-the-shelf CAR-T programs"]. FierceBiotech. Retrieved 12 October 2018.
27. ^Nisen, Max (11 October 2018). [https://www.bloomberg.com/view/articles/2018-10-11/allogene-stock-allo-rally-after-ipo-defies-market-rout "Allogene’s Monster Biotech IPO Defies Market Rout"]. Bloomberg. Retrieved 12 October 2018.
28. ^Mukherjee, Sy (11 October 2018). "Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO" Fortune. Retrieved 12 October 2018.
29. ^1 [https://www.bloomberg.com/research/stocks/private/person.asp?personId=9875245&privcapId=128240703 "Arie S. Belldegrun M.D., FACS"], Bloomberg Business. 9 March 2018. Retrieved on 9 March 2018.
30. ^"Kronos Bio". Kronos Bio. Retrieved 15 June 2018.
31. ^[https://vidaventures.com/vida-team/ "Team - Vida Ventures"]. Vida Ventures. Retrieved 15 May 2018.
32. ^[https://lsm.upenn.edu/program/advisory-board "Advisory Board"]. University of Pennsylvania. Retrieved 17 June 2016.
33. ^"Arie Belldegrun, MD, FACS". Two River. Retrieved 22 February 2018.
34. ^"Teva’s Arie Belldegrun resigns". The Pharma Letter. 27 January 2017. Retrieved 2 February 2017.
35. ^Melin, Anders & Chen, Caroline (11 June 2015). "Biotech CEOs among highest-paid US execs". Telegram.com. Retrieved 7 July 2015.
36. ^[https://www.hollywoodreporter.com/news/best-urologists-los-angeles-817766 "Hollywood's Top Doctors 2015: Best Urologists in Los Angeles"]. The Hollywood Reporter. 27 August 2015. Retrieved 15 June 2018.
37. ^"LA500-LA's Most Influential People". Los Angeles Business Journal. 2018. Retrieved 22 February 2018.
38. ^Lawrence, Carol (23 March 2018). "Laurels for Leaders: Aecom Boss Burke Highlights Class of Annual Honorees". Los Angeles Business Journal. Retrieved on 3 April 2018.
39. ^"CEO Today USA Awards 2017". CEO Today. 2018. Retrieved 22 February 2018.
40. ^[https://globenewswire.com/news-release/2018/06/13/1520949/0/en/UroGen-Pharma-s-Chairman-Arie-Belldegrun-MD-FACS-to-Receive-EY-2018-Master-Entrepreneur-Award.html "UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award"]. GlobeNewswire. 13 June 2018. Retrieved 15 June 2018.
41. ^[https://www.reuters.com/article/2009/09/29/idUS95321+29-Sep-2009+PRN20090929 "Nile Therapeutics Appoints Arie S. Belldegrun, M.D., to Board of Directors"]. Reuters. Retrieved 13 November 2013.
42. ^[https://www.reuters.com/article/2009/10/05/idUS138085+05-Oct-2009+PRN20091005 "US HIFU Appoints Arie Belldegrun, M.D. to Board of Directors"]. Reuters. Retrieved 13 November 2013.
43. ^[https://www.milkeninstitute.org/events/gcprogram.taf?function=bio&EventID=gc13&SPID=11121 "Global Conference 2013"] {{webarchive |url=https://web.archive.org/web/20131113061801/https://www.milkeninstitute.org/events/gcprogram.taf?function=bio&EventID=gc13&SPID=11121 |date=November 13, 2013 }}. Milken Institute. Retrieved 13 November 2013.
44. ^"Medical Symposia Keynote Addresses" {{webarchive |url=https://web.archive.org/web/20131113055744/http://www.kidneycancer.org/knowledge/learn/medical-education-cme/medical-symposia-keynote-addresses/ |date=November 13, 2013 }}. Kidney Cancer Association. Retrieved 13 November 2013.
45. ^"Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference". BizJournals (Charlotte). 7 January 2014. Retrieved 26 May 2014.
46. ^"Kite Pharma to Present at the 34th Annual J.P. Morgan Healthcare Conference". NASDAQ. 6 January 2016. Retrieved 6 January 2016.

External links

  • [https://www.bloomberg.com/research/stocks/people/person.asp?personId=9875245&ticker=KITE Arie Belldegrun on Bloomberg]
{{DEFAULTSORT:Belldegrun, Arie}}

24 : 1949 births|Living people|American bankers|American billionaires|American chairmen of corporations|American health care chief executives|American investors|American medical academics|American oncologists|American technology chief executives|American technology company founders|American urologists|American venture capitalists|Businesspeople from Los Angeles|Businesspeople in the pharmaceutical industry|Hebrew University of Jerusalem alumni|Israeli billionaires|Israeli emigrants to the United States|Israeli Jews|Jewish American bankers|Jewish physicians|People from Bel Air, Los Angeles|Physicians from California|Weizmann Institute of Science alumni
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/14 5:30:22